• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲联合政策应对精神障碍患者的 COVID-19 风险:一项伞式综述以及基于证据和共识的精神和公共卫生建议。

Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health.

机构信息

Psychiatry & Clinical Psychology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.

University Vita-Salute San Raffaele, Milan, Italy.

出版信息

Eur Psychiatry. 2022 Aug 16;65(1):e47. doi: 10.1192/j.eurpsy.2022.2307.

DOI:10.1192/j.eurpsy.2022.2307
PMID:35971656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9486830/
Abstract

As COVID-19 becomes endemic, identifying vulnerable population groups for severe infection outcomes and defining rapid and effective preventive and therapeutic strategies remains a public health priority. We performed an umbrella review, including comprehensive studies (meta-analyses and systematic reviews) investigating COVID-19 risk for infection, hospitalization, intensive care unit (ICU) admission, and mortality in people with psychiatric disorders, and outlined evidence- and consensus-based recommendations for overcoming potential barriers that psychiatric patients may experience in preventing and managing COVID-19, and defining optimal therapeutic options and current research priorities in psychiatry. We searched Web of Science, PubMed, and Ovid/PsycINFO databases up to 17 January 2022 for the umbrella review. We synthesized evidence, extracting when available pooled odd ratio estimates for the categories "any mental disorder" and "severe mental disorders." The quality of each study was assessed using the AMSTAR-2 approach and ranking evidence quality. We identified four systematic review/meta-analysis combinations, one meta-analysis, and three systematic reviews, each including up to 28 original studies. Although we rated the quality of studies from moderate to low and the evidence ranged from highly suggestive to non-significant, we found consistent evidence that people with mental illness are at increased risk of COVID-19 infection, hospitalization, and most importantly mortality, but not of ICU admission. The risk and the burden of COVID-19 in people with mental disorders, in particular those with severe mental illness, can no longer be ignored but demands urgent targeted and persistent action. Twenty-two recommendations are proposed to facilitate this process.

摘要

随着 COVID-19 成为地方病,确定易感染严重感染结局的脆弱人群群体,并定义快速有效的预防和治疗策略仍然是公共卫生的重点。我们进行了一项伞式综述,包括全面研究(荟萃分析和系统综述),调查了精神障碍患者 COVID-19 感染、住院、重症监护病房(ICU)入院和死亡的风险,并概述了克服精神障碍患者在预防和管理 COVID-19 方面可能遇到的潜在障碍的循证和共识建议,并确定了精神病学的最佳治疗选择和当前研究重点。我们搜索了 Web of Science、PubMed 和 Ovid/PsycINFO 数据库,截至 2022 年 1 月 17 日,进行了伞式综述。我们综合了证据,在可用时提取了“任何精神障碍”和“严重精神障碍”类别的汇总比值比估计值。使用 AMSTAR-2 方法和证据质量等级评估每个研究的质量。我们确定了四个系统评价/荟萃分析组合、一个荟萃分析和三个系统评价,每个系统评价都包括多达 28 项原始研究。尽管我们将研究质量评为从中等到低,并且证据范围从高度提示到无显著性,但我们发现了一致的证据表明,精神疾病患者感染 COVID-19、住院的风险增加,最重要的是死亡率增加,但 ICU 入院率没有增加。精神障碍患者,特别是严重精神疾病患者,COVID-19 的风险和负担不容忽视,但需要紧急采取有针对性和持续的行动。提出了 22 条建议来促进这一进程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1913/9486830/d12cf07b2f08/S0924933822023070_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1913/9486830/d12cf07b2f08/S0924933822023070_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1913/9486830/d12cf07b2f08/S0924933822023070_fig1.jpg

相似文献

1
Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health.欧洲联合政策应对精神障碍患者的 COVID-19 风险:一项伞式综述以及基于证据和共识的精神和公共卫生建议。
Eur Psychiatry. 2022 Aug 16;65(1):e47. doi: 10.1192/j.eurpsy.2022.2307.
2
Risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 mortality in people with pre-existing mental disorders: an umbrella review.患有精神障碍的人群中 SARS-CoV-2 感染、重症 COVID-19 疾病和 COVID-19 死亡率的风险:伞式综述。
BMC Psychiatry. 2023 Mar 20;23(1):181. doi: 10.1186/s12888-023-04641-y.
3
Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.精神障碍与 COVID-19 相关死亡率、住院和重症监护病房入院风险:系统评价和荟萃分析。
Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
COVID-19 and common mental health symptoms in the early phase of the pandemic: An umbrella review of the evidence.COVID-19 与大流行早期的常见心理健康症状:证据的伞式综述。
PLoS Med. 2023 Apr 25;20(4):e1004206. doi: 10.1371/journal.pmed.1004206. eCollection 2023 Apr.
6
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
7
Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.精准医疗,首次就诊:高度个性化和基于评估的青少年心理健康管理医疗模式。
Med J Aust. 2019 Nov;211 Suppl 9:S3-S46. doi: 10.5694/mja2.50383.
8
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树:影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
9
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
10
Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis.7 个国家的 COVID-19 患者心理健康障碍与死亡率之间的关联:系统评价和荟萃分析。
JAMA Psychiatry. 2021 Nov 1;78(11):1208-1217. doi: 10.1001/jamapsychiatry.2021.2274.

引用本文的文献

1
Examining self-described policy-relevant evidence base for policymaking: an evidence map of COVID-19 literature.审视自认为与政策制定相关的决策证据基础:一份关于新冠疫情文献的证据图谱
BMJ Public Health. 2024 Aug 28;2(2):e000694. doi: 10.1136/bmjph-2023-000694. eCollection 2024 Dec.
2
Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder.精神分裂症和分裂情感性障碍患者对SARS-CoV-2 mRNA疫苗的抗刺突抗体反应。
Brain Behav Immun Health. 2024 Jun 3;38:100802. doi: 10.1016/j.bbih.2024.100802. eCollection 2024 Jul.
3
Patients with psychosis spectrum disorders hospitalized during the COVID-19 pandemic unravel overlooked SARS-CoV-2 past infection clustering with HERV-W ENV expression and chronic inflammation.

本文引用的文献

1
COVID-19 and severe mental illness in Israel: testing, infection, hospitalization, mortality and vaccination rates in a countrywide study.COVID-19 与以色列严重精神疾病:全国性研究中的检测、感染、住院、死亡率和疫苗接种率。
Mol Psychiatry. 2022 Jul;27(7):3107-3114. doi: 10.1038/s41380-022-01562-2. Epub 2022 Apr 22.
2
Association between serum lithium level and incidence of COVID-19 infection.血清锂水平与新型冠状病毒肺炎感染发生率之间的关联。
Br J Psychiatry. 2022 Jul;221(1):425-427. doi: 10.1192/bjp.2022.42.
3
Rational Approach to Psychotropic Use in COVID-19 Cases With Psychiatric Comorbidities: Lesson Learnt From a Case Series.
COVID-19 大流行期间住院的精神病谱系障碍患者揭示了 SARS-CoV-2 过去感染与 HERV-W ENV 表达和慢性炎症的被忽视聚集。
Transl Psychiatry. 2023 Jul 31;13(1):272. doi: 10.1038/s41398-023-02575-3.
4
Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact.新冠后状况:药物和诊断测试的配给作为医疗保健影响的替代指标。
Intern Emerg Med. 2023 Apr;18(3):801-809. doi: 10.1007/s11739-023-03228-5. Epub 2023 Mar 21.
5
A closer look at yoga nidra- early randomized sleep lab investigations.深入了解瑜伽睡眠术——早期随机睡眠实验室研究。
J Psychosom Res. 2023 Mar;166:111169. doi: 10.1016/j.jpsychores.2023.111169. Epub 2023 Jan 29.
6
Impact of mental disorders on clinical outcomes of physical diseases: an umbrella review assessing population attributable fraction and generalized impact fraction.精神障碍对躯体疾病临床结局的影响:一项评估人群归因分数和广义影响分数的综合综述
World Psychiatry. 2023 Feb;22(1):86-104. doi: 10.1002/wps.21068.
COVID-19合并精神疾病患者使用精神药物的合理方法:来自一系列病例的经验教训
Indian J Psychol Med. 2021 Nov;43(6):542-545. doi: 10.1177/02537176211040260. Epub 2021 Sep 28.
4
COVID-19 vaccine hesitancy in patients with mental illness: strategies to overcome barriers-a review.精神疾病患者对COVID-19疫苗的犹豫态度:克服障碍的策略——一项综述
J Egypt Public Health Assoc. 2022 Jan 21;97:5. doi: 10.1186/s42506-022-00102-8. eCollection 2022 Dec.
5
Mechanisms of action of fluvoxamine for COVID-19: a historical review.氟伏沙明治疗 COVID-19 的作用机制:历史回顾。
Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3. Epub 2022 Jan 7.
6
COVID-19 Vaccination Rates in a Cohort Study of Patients With Mental Illness in Residential and Community Care.一项针对居住和社区护理中精神疾病患者的队列研究中的新冠疫苗接种率
Front Psychiatry. 2021 Dec 16;12:805528. doi: 10.3389/fpsyt.2021.805528. eCollection 2021.
7
All-cause and cause-specific mortality in people with mental disorders and intellectual disabilities, before and during the COVID-19 pandemic: cohort study.COVID-19大流行之前及期间,精神障碍和智力残疾患者的全因死亡率和特定病因死亡率:队列研究
Lancet Reg Health Eur. 2021 Dec;11:100228. doi: 10.1016/j.lanepe.2021.100228. Epub 2021 Oct 7.
8
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.氟伏沙明治疗 SARS-CoV-2 感染的早期治疗:当前证据综述。
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
9
Access to Mental Health Care during the First Wave of the COVID-19 Pandemic in Italy: Results from the COMET Multicentric Study.意大利新冠疫情第一波期间的心理健康护理可及性:COMET多中心研究结果
Brain Sci. 2021 Oct 26;11(11):1413. doi: 10.3390/brainsci11111413.
10
Antipsychotics and COVID-19: the debate goes on - Authors' reply.抗精神病药物与2019冠状病毒病:争论仍在继续——作者回复
Lancet Psychiatry. 2021 Dec;8(12):1030-1031. doi: 10.1016/S2215-0366(21)00428-4.